Ajay Devgn moves Bombay HC over FDA’s pan masala ad notice
State Food and Drug Administration (FDA) Commissioner Tukaram Mundhe stated that actor Ajay Devgn has filed a petition in the Bombay High Court regarding a show-cause notice issued for promoting Vimal Elaichi pan masala. The FDA previously served similar notices to actors Shah Rukh Khan and Tiger Shroff, requiring them to remove advertisements and explain their involvement in endorsing the brand. Mundhe confirmed that administrative hearings have concluded and an adjudication case will be filed with the joint commissioner soon, noting that legal proceedings will continue unless the court issues specific directions. The FDA requested detailed information on endorsement contracts and evidence of the product's availability, highlighting that Vimal Pan Masala is a prohibited smokeless tobacco item in the state. The article contextualizes this regulatory action within India's significant public health crisis, citing national data that attributes approximately 30% of global oral cancer cases to the country, driven largely by smokeless tobacco consumption.
Bollywood actor Ajay Devgn has challenged a regulatory directive from the Maharashtra Food and Drugs Administration in the Bombay High Court, describing the agency’s actions as a mere farce and an empty formality. In a petition filed on October 15, Devgn argued that the show-cause notice served on him in August was premeditated and predetermined. A division bench comprising Chief Justice Mahesh Chandra Tripathi and Justice Advait Sethna is scheduled to hear the petition on November 4. The legal dispute centers on Devgn’s endorsement of Vimal Elaichi, a product the state regulator contends functions as surrogate advertising for prohibited smokeless tobacco items. The conflict began on August 16, 2026, when the Maharashtra FDA issued notices to Devgn, along with actors Shah Rukh Khan and Tiger Shroff. Under the Food Safety and Standards Act of 2006, the agency stated that their participation in Vimal brand advertisements violated statutory provisions. The administration claimed that promoting Vimal Elaichi effectively promoted Vimal Pan Masala and Gutkha, products banned in Maharashtra. Consequently, the actors were ordered to halt their involvement in the campaigns, remove promotional content from digital platforms, and submit due diligence records. The FDA cited Section 24 of the Food Safety and Standards Advertising and Claims Regulations of 2018, asserting that public figures bear accountability for endorsements and cannot claim ignorance of the brand’s association with prohibited goods. Devgn responded to the notice on August 21, maintaining that he had solely endorsed Vimal Elaichi, a product legally available in the market. He denied any connection to Vimal Pan Masala and stated that the advertisement did not reference other products. He further clarified that he had conducted due diligence prior to accepting the role and had no control over the broadcast or business operations. Despite this response, the FDA proceeded with its investigation. On September 14, the Delhi High Court rejected a separate challenge brought by PB Agro LLP, a licensee for the Vimal brand. The court ruled it lacked territorial jurisdiction, identifying Maharashtra as the appropriate forum for such disputes while leaving the legality of the campaign undecided. In his current petition, Devgn argues that the FDA’s directives exceeded the scope of a standard show-cause notice. He contends that the agency erroneously conflated Vimal Elaichi with Vimal Pan Masala and approached the matter with a closed mind, effectively deeming him guilty before hearing his defense. The actor described the order to discontinue participation in a lawful advertisement as an unreasonable restriction on his constitutional right to practice his profession. He characterized the administrative action as arbitrary and malicious, violating principles of natural justice. Meanwhile, the regulatory body continues its internal processes. On October 30, FDA Commissioner Tukaram Mundhe announced at a press conference that the initial hearings before the Assistant Commissioner had concluded. Mundhe stated that the Designated Officer intended to file an adjudication case before the Joint Commissioner within the following week. Although Devgn has sought judicial intervention, Mundhe confirmed that the department would continue its proceedings according to established rules unless the court issues specific directions otherwise. The Joint Commissioner holds the authority to adjudicate the final outcome of these cases. The broader context involves strict state regulations against smokeless tobacco. Vimal Pan Masala is classified as a prohibited item in Maharashtra, banning its manufacture, storage, transport, and sale. The FDA emphasized that the Vimal brand is prominently linked to these restricted products. While the actors have not made extensive public statements regarding the initial notices, Devgn’s recent legal move highlights the tension between celebrity endorsements and state-level health regulations. The industry faces scrutiny over how surrogates are defined, particularly given India’s significant burden of oral cancer attributed to smokeless tobacco consumption. The upcoming hearing in Bombay will determine whether the regulatory approach withstands constitutional scrutiny.
Bollywood actor Ajay Devgn has filed a petition in the Bombay High Court to challenge a show-cause notice issued by the Maharashtra Food and Drug Administration regarding his appearances in Vimal Elaichi advertisements. The FDA initially accused Devgn, along with Shah Rukh Khan and Tiger Shroff, of promoting prohibited pan masala products through these ads. On October 30, 2026, FDA Commissioner Tukaram Mundhe announced that the initial administrative proceedings against the three actors had concluded and the matter would proceed to adjudication before the Joint Commissioner. Devgn’s legal team argues that the notice was improperly served on the actor rather than the manufacturing company and contends that he is no longer associated with the brand. A previous attempt to quash the notices in the Delhi High Court was rejected, with the court directing the parties to seek relief in Maharashtra.
Bias read (Center): The report relies exclusively on official statements from the FDA and court records, presenting the legal dispute neutrally without editorializing or favoring either the regulatory body or the celebrity.
Why factuality (95): Highly accurate and detailed. Correctly dates the FDA statement (Oct 30, 2026) and mentions the specific date of the potential hearing (Nov 4). Includes relevant background on the Delhi High Court dismissal, providing a comprehensive picture of the legal landscape. Faithful to the likely primary sou
Why objectivity (95): Very neutral and balanced. Presents the FDA's position and the actor's petition side-by-side without favoring either. Uses standard reporting language ('stated,' 'contended,' 'alleged') to attribute claims appropriately.
State Food and Drug Administration (FDA) Commissioner Tukaram Mundhe stated that actor Ajay Devgn has filed a petition in the Bombay High Court regarding a show-cause notice issued for promoting Vimal Elaichi pan masala. The FDA previously served similar notices to actors Shah Rukh Khan and Tiger Shroff, requiring them to remove advertisements and explain their involvement in endorsing the brand. Mundhe confirmed that administrative hearings have concluded and an adjudication case will be filed with the joint commissioner soon, noting that legal proceedings will continue unless the court issues specific directions. The FDA requested detailed information on endorsement contracts and evidence of the product's availability, highlighting that Vimal Pan Masala is a prohibited smokeless tobacco item in the state. The article contextualizes this regulatory action within India's significant public health crisis, citing national data that attributes approximately 30% of global oral cancer cases to the country, driven largely by smokeless tobacco consumption.
Bias read (Center): The reporting relies exclusively on official statements from the FDA commissioner and cites objective public health statistics, presenting the regulatory dispute without employing loaded language or favoring either the industry or the enforcement agency.
Why factuality (95): Accurately reflects the core facts: the FDA notice, the move to the Bombay High Court, the involvement of other actors, and the status of the adjudication process. It aligns well with the cross-source consensus. The inclusion of specific statistics on oral cancer adds context but is presented neutra
Why objectivity (90): Maintains a neutral, journalistic tone. Reports the FDA commissioner's statements directly without injecting opinion. The addition of health statistics provides context rather than bias.
Bollywood actor Ajay Devgn has challenged a show-cause notice issued by the Maharashtra Food and Drugs Administration regarding his endorsement of the 'Vimal Elaichi' chewing product. In a petition filed with the Bombay High Court, Devgn described the regulatory action as a 'mere farce,' arguing that the FDA improperly equated his specific endorsement of Vimal Elaichi with the banned Vimal Pan Masala. The FDA had previously issued similar notices to Shah Rukh Khan and Tiger Shroff, citing violations of the Food Safety and Standards Act due to the Vimal brand's association with prohibited gutkha products. Devgn maintains that he conducted due diligence and that the specific product he advertised is legally sold in the market. A high court bench is scheduled to hear the actor's petition on November 4.
Bias read (Progressive): The headline and lead emphasize the celebrity's dismissal of the regulator as a 'farce' rather than detailing the legal basis for the ban, framing the story around individual rights versus bureaucratic overreach.
Why factuality (90): Correctly identifies the legal arguments made by Devgn and the timeline of events. However, it relies heavily on quoting the petitioner's strong language ('farce', 'mala fide') as the lead, which frames the story around the actor's perspective rather than the procedural update. The text appears cut
Why objectivity (75): Less objective than Article 0 because it leads with the actor's subjective characterization of the FDA's actions as a 'farce' and 'empty formality.' While these are quotes, the headline and opening sentence emphasize the actor's negative view of the regulatory body, creating a slight narrative tilt
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.